Health Maintenance: We can do more
Health Maintenance: We can do more The amoeba is a single-cell organism that you might recall from high school biology. Single-cell organisms reproduce asexually. That is, from time to time, if food is plentiful, an amoeba splits in two. Importantly, when an amoeba divides, it does not create an ‘old’ and a ‘young’ amoeba; it simply creates two amoebas from the same cell. In fact, if you waited for any amoeba to ‘grow old and die’, picking one of the two amoebas at random at each division, you would wait indefinitely. An amoeba is like a car that comes with a very proactive mechanic inside. Amoebas can be damaged by the environment, and they experience wear and tear. However, amoebas can repair themselves faster than they break down. Unless severely damaged by their environment or starved, amoebas are immortal. That is, they can indefinitely repair the normal wear and tear of living faster than it occurs. Amoebas are evidence that biology and death are not inseparable. Amoebas do not die because of age. Like an automobile paired with a good mechanic, amoebas demonstrate that living cells can be maintained indefinitely. Can we be maintained indefinitely like amoebas? Unlike cars, we are alive. Unlike amoebas, we are multicellular. However, like cars and amoebas, we can be maintained to improve our health and lifespan. Our individual cells actively maintain themselves. Like amoebas, our cells routinely repair damage done to their DNA, clear out accumulating waste, and replace worn-out organelles. However, unlike amoebas, our cells are not as effective in reversing damage, and eventually they degrade over time. It is likely that we will one day improve upon our own cellular repair mechanisms, but the fact that we are composed of trillions of cells complicates this maintenance approach. Not only is it difficult to operate on trillions of cells with disparate functions, but as multicellular organisms, we use selective cell death for normal tissue replacement, and as a strategy for staying healthy (an approach that amoebas cannot take for obvious reasons). As within our individual cells, our bodies also actively maintain themselves on the tissue level. Damaged cells are replaced, and injuries are healed by new cells resulting from cell division. When it comes to tissue repair, stem cells are the master mechanics of our bodily systems. Directly, or through the cells they create, stem cells not only help heal us after injury, but they continually replenish the blood and immune system, and rebuild our bone, muscle, connective tissue, and vasculature. In fact, stem cells contribute to maintenance of most organs and systems of the body. Environmental and Internal Damage However, as with most of our cells, our stem cells experience environmental and internal damage that causes them to become less effective at tissue maintenance, and eventually they either shut down or die off. Because our stem cell populations diminish as we grow older, the tissues that they maintain eventually fall into disrepair as well. Left to its own devices, our biology eventually falls short when it comes to maintenance and repair. However, where knowledge and technology have presented us the opportunity, we have taken matters into our own hands. For example, we clean out or bypass clogged arteries, we remove inflamed appendixes, we replace worn out knees and hips, we reshape eye lenses with lasers, and we swap out dysfunctional organs for new ones. As our understanding of our own biology increases, and as our ability to operate upon it improves, we will continue to practice better maintenance of the human body. We founded Forever Labs to introduce a new method to our repertoire of health maintenance strategies. There now exists compelling evidence that replenishing our aged stem cell population with our own younger stem cells may significantly improve our health, and perhaps, even increase our lifespan. In my next blog post, I will discuss our new method of health maintenance, and how we are going to implement it.
Access Original Research
View the complete study and detailed methodology from the original source.
Read Full Study →Related Articles
Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial
OBJECTIVE To assess in multiple sclerosis (MS) the effect of intense immunosuppression followed by autologous hematopoietic stem cells transplantation (AHSCT) vs mitoxantrone (MTX) on disease activity measured by MRI. METHODS We conducted a multicenter, phase II, randomized trial including patients with secondary progressive or relapsing-remitting MS, with a documented increase in the last year on the Expanded Disability Status Scale, in spite of conventional therapy, and presence of one or more gadolinium-enhancing (Gd+) areas. Patients were randomized to receive intense immunosuppression (mobilization with cyclophosphamide and filgrastim, conditioning with carmustine, cytosine-arabinoside, etoposide, melphalan, and anti-thymocyte globulin) followed by AHSCT or MTX 20 mg every month for 6 months. The primary endpoint was the cumulative number of new T2 lesions in the 4 years following randomization. Secondary endpoints were the cumulative number of Gd+ lesions, relapse rate, and disability progression. Safety and tolerability were also assessed. Twenty-one patients were randomized and 17 had postbaseline evaluable MRI scans. RESULTS AHSCT reduced by 79% the number of new T2 lesions as compared to MTX (rate ratio 0.21, p = 0.00016). It also reduced Gd+ lesions as well as the annualized relapse rate. No difference was found in the progression of disability. CONCLUSION Intense immunosuppression followed by AHSCT is significantly superior to MTX in reducing MRI activity in severe cases of MS. These results strongly support further phase III studies with primary clinical endpoints.
Effect of aging on stem cells
As we age, stem cells lose efficacy and ability to heal.
Intravenous transplantation of bone marrow-derived mononuclear cells prevents memory impairment in transgenic mouse models of Alzheimer's disease
Intravenous transplantation of bone marrow-derived mononuclear cells (BMMCs) successfully improved cognitive function and prevented neurodegeneration in two different Alzheimer's disease mouse models.